Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
ADMA Biologics Inc(ADMA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ADMA
09/25/2026: ADMA (2-star) is currently NOT-A-BUY. Pass it for now.
ADMA Biologics is a specialized biotechnology company that focuses on developing and marketing plasma-derived therapies for immune-compromised patients. The company has a notable position due to its vertically integrated model, which allows it to control both raw plasma collection and final product manufacturing. Its primary growth story centers on the successful commercial adoption of its key products, BIVIGAM and ASCENIV. Investors must weigh these operational strengths against risks such as intense competition from major global players and execution challenges in complex manufacturing. The stock may best suit growth-oriented investors who can tolerate volatility, while future developments to monitor include plasma supply consistency and continued market share penetration.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an active commercial expansion phase with significant revenue growth potential. |
| Momentum investor | Strong fit while signal remains positive | The stock has shown strong price performance associated with its recent commercial execution. |
| Value investor | Mixed fit | Valuation is often driven by growth expectations rather than current earnings multiples. |
| Dividend investor | Weak fit | The company does not pay dividends, focusing on growth capital. |
| Low-risk investor | Weak fit | Biotechnology stocks are inherently volatile due to regulatory and clinical risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience sharp price movements based on news and market sentiment. |
| Valuation risk | Medium / high | Growth expectations are heavily priced in, leaving little room for operational disappointments. |
| Competition risk (Plasma-derived product competition) | High | Large global players have significant scale advantages in pricing and supply. |
| Business quality | Medium | The business is improving but still faces execution challenges in a highly regulated industry. |
| Dividend income | Low / none | There is no dividend income for investors. |
| Execution risk | Medium / high | Maintaining complex manufacturing processes and plasma supply is essential for operational success. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 126.56% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.10B USD | Price to earnings Ratio 13.4 | 1Y Target Price 17 |
Price to earnings Ratio 13.4 | 1Y Target Price 17 | ||
Volume (30-day avg) 2.5M shares | Beta 0.77 | 52 Weeks Range 7.21 - 20.46 | Updated Date 09/25/2026 |
52 Weeks Range 7.21 - 20.46 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.7 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Specialty Biologics Sales | Revenue from sales of BIVIGAM, ASCENIV, and NABI-HB to hospitals and specialty pharmacies. | The primary way the company makes money is by selling life-saving plasma-derived medicines. |
| Plasma Collection Services | Operations of ADMA BioCenters providing plasma, some of which may be sold to third parties. | The company controls its supply chain by collecting its own raw material. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 13.4 | Forward PE 9.78 | Enterprise Value 2.24B | Price to Sales(TTM) 4.1 |
Enterprise Value 2.24B | Price to Sales(TTM) 4.1 | ||
Enterprise Value to Revenue 4.37 | Enterprise Value to EBITDA 9.61 | Shares Outstanding 223.98M | Shares Floating 219.66M |
Shares Outstanding 223.98M | Shares Floating 219.66M | ||
Percent Insiders 1.97 | Percent Institutions 93.21 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About ADMA Biologics Inc
Exchange NASDAQ | Headquarters Ramsey, NJ, United States | ||
IPO Launch date 2013-10-17 | Co-Founder, President, CEO & Director Mr. Adam S. Grossman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 640 | Website https://www.admabiologics.com |
Full time employees 640 | Website https://www.admabiologics.com | ||
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.